Trials / Completed
CompletedNCT02230254
PE PREMIER CHINA CLINICAL TRIAL
PE PREMIER China: A Prospective, Multicenter Trial to Assess the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 101 (actual)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
PE PREMIER China: A Prospective, Multicenter Trial to Assess the Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
Detailed description
To evaluate clinical and peri-procedural angiographic outcomes for the Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) ≤34 mm in length (by visual estimate) in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Percutaneous coronary intervention PROMUS PREMIER | PROMUS PREMIER |
Timeline
- Start date
- 2014-04-09
- Primary completion
- 2014-06-22
- Completion
- 2015-07-31
- First posted
- 2014-09-03
- Last updated
- 2022-05-12
- Results posted
- 2022-05-12
Source: ClinicalTrials.gov record NCT02230254. Inclusion in this directory is not an endorsement.